Standard Six-Month Drug Regimen for Drug-Sensitive Pulmonary Tuberculosis in India
The standard six-month regimen for drug-sensitive pulmonary tuberculosis consists of 2 months of isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol (E), followed by 4 months of isoniazid and rifampin, abbreviated as 2HRZE/4HR 1, 2, 3.
Intensive Phase (First 2 Months): 2HRZE
The initial intensive phase includes four drugs administered daily:
- Isoniazid: 5 mg/kg/day (typically 300 mg daily for adults)
- Rifampin: 10 mg/kg/day (typically 600 mg daily for adults)
- Pyrazinamide: 25 mg/kg/day
- Ethambutol: 15 mg/kg/day
All medications should be taken together as a single dose, preferably on an empty stomach (30 minutes to 1 hour before meals or 2 hours after) 2.
Continuation Phase (Next 4 Months): 4HR
After completing the intensive phase, continue with two drugs:
- Isoniazid: 5 mg/kg/day
- Rifampin: 10 mg/kg/day
These are administered daily for the remaining 4 months 1, 2.
Critical Adjunctive Therapy
Pyridoxine (Vitamin B6) at 25-50 mg daily should be given with isoniazid to all patients to prevent peripheral neuropathy 4, 1.
Important Clinical Considerations
When This Regimen Applies
This standard 6-month regimen is appropriate for:
- Drug-susceptible pulmonary tuberculosis
- Both HIV-positive and HIV-negative patients (efficacy is equivalent when treatment is completed) 2
- Adults and children (with weight-adjusted dosing)
- Both smear-positive and smear-negative cases
When This Regimen Should NOT Be Used
Do not use the standard 6-month regimen for:
- TB affecting the central nervous system, bones, or joints
- Miliary TB
- Pericardial TB
- Drug-resistant TB (requires different regimens)
These conditions require longer treatment durations 4.
Monitoring Requirements
Monthly clinical follow-up is recommended during treatment to assess:
- Treatment adherence
- Adverse drug reactions
- Clinical response to therapy
- Development of drug resistance
Common Pitfalls to Avoid
Extending treatment unnecessarily: Studies show that 60% of cases in some settings had treatment prolonged without obvious reason 5. If the standard regimen is completed and the patient has drug-susceptible TB, extending beyond 6 months is not necessary 2.
Omitting ethambutol inappropriately: While some clinicians consider excluding ethambutol in low-risk children, drug resistance prevalence can be difficult to ascertain. Most experts include ethambutol in the intensive phase 1.
Poor adherence: The regimen's effectiveness depends on completion. Directly observed therapy (DOT) for at least 5 of 7 days per week is recommended to ensure adherence 4.
Context for India
While the 2025 ATS/CDC/ERS/IDSA guidelines now recommend shorter 4-month regimens for eligible patients with drug-susceptible pulmonary TB 4, the traditional 6-month regimen (2HRZE/4HR) remains the standard in most settings globally, including India, and achieves relapse-free recovery in more than 97% of patients with non-resistant strains 3. The newer 4-month regimens require specific drugs (rifapentine, moxifloxacin) that may not be universally available in all Indian settings.